20 Sep 2021 11:03
MGC Pharmaceuticals Ltd.
PDMR Notification
20 September 2021
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a European based bio-pharma company specialising in the production and development of phytomedicines, wishes to advise that the following Person Discharging Managerial Responsibilities (PDMR) has been issued shares in MGC Pharma. This notification is made in accordance with UK Market Abuse Regulations.
The shares the subject of this notice were issued to the PDMR in accordance with a share purchase agreement executed by MGC Pharma and the owners of MediCaNL Inc in April 2021. The issued shares are part of the purchase consideration payable by MGC Pharma to the PDMR who was a shareholder of MediCaNL Inc.
A copy of the Announcement made on 22 April 2021 which summaries the terms of the corporate acquisition can be found at the following URL:
https://www.asx.com.au/asxpdf/20210422/pdf/44vrj4zvy8ztjr.pdf
1 | Details of the person discharging managerial responsibilities/person closely associated
| ||||
(a) | Name | Nadya Lisovoder | |||
2 | Reason for the notification
| ||||
(a) | Position
| Leading CRO | |||
(b) | Initial notification/amendment
| Initial | |||
(c) | If amendment: reason
| n/a | |||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
Full name of entity | MGC Pharmaceuticals Limited
| ||||
Legal Entity Identifier Code | 213800HRE3FQJ6RK4H10
| ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
| ||||
(a) | Description of the financial instrument, type of instrument | Fully Paid Ordinary Shares | |||
(b) | Identification Code (ISIN)
| AU000000MXC6 | |||
(c) | Nature of transaction | Shares issued as consideration for a corporate entity acquired by the Issuer. | |||
(d) | Currency | Price | Volume | Total | |
AUD | $0.067 | 13,442,366 | $900,000 | ||
Aggregated information | |||||
AUD | $0.067 | 13,442,366 | $900,000 | ||
(e) | Date of transaction
| 2021-09-20 | |||
(f) | Place of transaction
| Outside a trading venue | |||
--Ends--
Authorised for release by the Company Secretary, for further information please contact:
MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6382 3390 info@mgcpharma.com.au | MGC Pharmaceuticals Ltd David Lim Company Secretary +61 8 6382 3390 info@mgcpharma.com.au |
UK Broker - Turner Pope Andy Thacker +44 203 657 0050 info@turnerpope.com | UK PR Advisors - Tavistock Charles Vivian / Tim Pearson +44 207 920 3150 mgcpharma@tavistock.co.uk
|
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline.
Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.
MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.
Follow us through our social media channels:
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma